Phase 1 Study of ART5803 in Healthy Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

September 10, 2025

Study Completion Date

April 8, 2026

Conditions
Autoimmune Encephalitis
Interventions
DRUG

ART5803

A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.

Trial Locations (1)

3004

Nucleus Network Pty Ltd, Melbourne

Sponsors
All Listed Sponsors
lead

Arialys Therapeutics

INDUSTRY